CAM
CNCE

Cormorant Asset Management’s Concert Pharmaceuticals, Inc. CNCE Stock Holding History

Cormorant Asset Management’s Portfolio CNCE Stock Details CNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-538,422
Closed -$5.54M – 79
2016
Q4 		$5.54M Buy
+538,422
New +$4.92M 0.75% 38

Other funds holding CNCE

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cormorant Asset Management's CNCE Position: Q1 2017 in Review

Cormorant Asset Management sold out of Concert Pharmaceuticals, Inc. (CNCE) in Q1 2017, closing a stake of 538,422 shares — an estimated $5.54M sold.

Cormorant Asset Management first reported a position in CNCE in Q4 2016 and held it in 1 quarter. The position peaked at $5.54M in Q4 2016. 85 funds tracked by Wall St. Rank hold CNCE as of Q1 2017.

  • Cormorant Asset Management reported no remaining Concert Pharmaceuticals, Inc. position as of Q1 2017 after selling out during the quarter.
  • Cormorant Asset Management sold 538,422 Concert Pharmaceuticals, Inc. shares in Q1 2017, an estimated $5.54M.
  • Cormorant Asset Management first reported a position in Concert Pharmaceuticals, Inc. in Q4 2016 and held it in 1 quarter.
  • Cormorant Asset Management's Concert Pharmaceuticals, Inc. position peaked at $5.54M in Q4 2016.
  • 85 funds tracked by Wall St. Rank held Concert Pharmaceuticals, Inc. as of Q1 2017.

Based on Cormorant Asset Management's 13F filing for Q1 2017, filed 15 May 2017.